NDRC Holds Seminar on Pharmaceutical Industry Policies; Johnson & Johnson Forecasts $400M Profit Loss Due to Tariffs
Johnson & Johnson
Medical Device R&D and Manufacturer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
Innovative drugs receive top-level attention.
On April 16, the Price Cost and Certification Center of the National Development and Reform Commission organized a seminar on relevant policies for the pharmaceuticals industry. The meeting was chaired by Deputy Director Chu Zhan, and representatives from biopharmaceutical enterprises and experts from industry research institutions engaged in discussions on promoting high-quality development of the pharmaceuticals industry, offering opinions and suggestions for improving industrial policies.
Johnson & Johnson Discloses Tariff Impact for the First Time.
On April 16, Johnson & Johnson disclosed in its earnings report for the first time that tariffs are expected to result in a $400 million profit loss for the company by 2026. This $400 million loss covers various tariff impacts, including import tariffs imposed by Canada and Mexico that exceed the scope of the North American trade agreement. Tariffs may also alter the cost structure of Johnson & Johnson's products, with some costs reflected on the balance sheet as inventory and adjusted through the income statement in the future.
In the past day, what are the hot topics in the pharmaceutical market in China and abroad that are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) The Price Cost and Certification Center of the National Development and Reform Commission Organized a Symposium on Relevant Policies of the Pharmaceutical Industry
On April 16, the Price Cost and Certification Center of the National Development and Reform Commission organized a symposium on relevant policies for the pharmaceuticals industry. The meeting was presided over by Deputy Director Chu Zhan, and representatives from biopharmaceutical enterprises and experts from industry research institutions engaged in discussions on promoting high-quality development of the pharmaceuticals industry, offering opinions and suggestions for improving industry-related policies.
2) Heliocare Biotech signs strategic cooperation agreement with Beijing Tiantan Hospital, Capital Medical University
On April 16, Heliocare Biotech announced that it had recently signed a strategic cooperation agreement with Beijing Tiantan Hospital, Capital Medical University. Relying on the technical advantages of cell and gene therapy, the collaboration will deeply integrate Tiantan Hospital's clinical resources and academic accumulation to accelerate the transformation of research achievements into clinical value.
3) Neusoft Group signs strategic cooperation agreement with Foshan Municipal Government
Recently, Neusoft Group signed a strategic cooperation agreement with the Foshan Municipal Government to carry out comprehensive cooperation in the field of healthcare. The two parties will jointly build a city-level health and wellness service operation platform driven by public data, deeply empowering the Foshan health and wellness industry ecosystem with AI and big data technologies. This collaboration aims to create a dual-driven model of "a strong manufacturing city" and "a renowned wellness hub," providing a "Foshan Solution" for China to address aging challenges.
/ 02 /
Capital Information
1) After the reverse acquisition, Genor Biopharma submits its listing application again
On April 15, according to the Hong Kong Stock Exchange's official website, Genor Biopharma submitted a listing application to the Hong Kong Stock Exchange. This is not an IPO application but rather Genor Biopharma, after a reverse takeover, will be treated as a new listing applicant.
/ 03 /
Pharmaceutical News
1) Kanghong Biotech's Injectable KH815 Receives Clinical Approval
On April 16, according to the CDE official website, Kanghong Biologics' injectable KH815 received clinical approval and is proposed for research in the treatment of advanced solid tumors.
2) The First US Phase 2/3 Clinical Trial of EGFR/HER3 ADC Initiated
On April 15, according to the Clinicaltrials.gov website, Baili Tianhe's EGFR/HER3 ADC new drug BL-B01D1 head-to-head first-line treatment for locally recurrent, metastatic, or metastatic triple-negative breast cancer patients who are not suitable for PD-1, with the development code IZABRIGHT-Breast01, is led by Bristol-Myers Squibb.
/ 04 /
Overseas Pharmaceutical News
1) Johnson & Johnson Projects $400 Million Profit Loss Due to Tariffs
On April 16, Johnson & Johnson disclosed in its earnings report for the first time that tariffs are expected to result in a $400 million profit loss for the company by 2026. This $400 million loss covers various tariff impacts, including import tariffs imposed by Canada and Mexico that exceed the scope of the North American trade agreement. Tariffs may also alter the cost structure of Johnson & Johnson's products, with some costs reflected on the balance sheet for inventory and adjusted through the income statement in the future.
PS: Welcome to scan the QR code below to add Amino's WeChat for communication.